Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q2 2026 › vs Q1 2026
Arcturus Therapeutics Holdings (ARCT) Q2 2026 vs Q1 2026 (quarter over quarter)
Arcturus Therapeutics Holdings's revenue rose $898K (+44%) from $2.1M in Q1 2026 to $3.0M in Q2 2026. The biggest changes: Grant +$628K (+43%); Collaboration Revenue +$270K (+44%).
Arcturus Therapeutics Holdings, Q2 2026: revenue $3.0M (-90% year over year), operating margin -863.3%, net loss $23.8M, operating cash flow −$19.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Grant | $2.1M | $1.5M | $628K | +43% |
| Collaboration Revenue | $880K | $610K | $270K | +44% |
| Revenue | $3.0M | $2.1M | $898K | +44% |
| Other income, net | $1.8M | $2.0M | −$207K | -11% |
| Net loss | $23.8M | $27.0M | −$3.2M | -12% |
| Costs & expenses | $28.5M | $31.0M | −$2.5M | -8% |
| Operating costs | $28.5M | $31.0M | −$2.5M | -8% |
| Research & development | $17.5M | $21.5M | −$4.0M | -19% |
| General & admin | $11.0M | $9.5M | $1.5M | +16% |
| Operating cash sources | $24.7M | $24.4M | $317K | +1% |
| Depreciation & amortization | $600K | $658K | −$58K | -9% |
| Share-based compensation | $4.2M | $4.3M | −$94K | -2% |
| Cash used in operations | $19.9M | $19.4M | $469K | +2% |
| Net loss absorbed | $23.8M | $27.0M | −$3.2M | -12% |
| Working capital & other | $956K | −$2.5M | $3.5M | — |
Questions
How much did Arcturus Therapeutics Holdings's revenue grow quarter over quarter in Q2 2026?
Arcturus Therapeutics Holdings's revenue rose $898K (+44%) from $2.1M in Q1 2026 to $3.0M in Q2 2026.
What drove Arcturus Therapeutics Holdings's revenue change in Q2 2026?
Grant +$628K (+43%); Collaboration Revenue +$270K (+44%).